Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of Genius Sports Limited (NYSE: GENI) closed at $11.26 in the last session, up 4.45% from day before closing price of $10.78. In other words, the price has increased by $4.45 from its previous closing price. On the day, 3.6 million shares were traded. GENI stock price reached its highest trading level at $11.28 during the session, while it also had its lowest trading level at $10.725.
Ratios:
We take a closer look at GENI’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.72 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 43.72. For the most recent quarter (mrq), Quick Ratio is recorded 1.73 and its Current Ratio is at 1.73. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In the most recent recommendation for this company, Wells Fargo on November 18, 2025, initiated with a Equal Weight rating and assigned the stock a target price of $10.
On September 12, 2025, Roth Capital started tracking the stock assigning a Buy rating and target price of $16.
On July 25, 2025, Northland Capital started tracking the stock assigning a Outperform rating and target price of $14.Northland Capital initiated its Outperform rating on July 25, 2025, with a $14 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jan 05 ’26 when Davison Jack bought 202,876 shares for $11.11 per share.
Taylor Nicholas Charles Fraser bought 162,737 shares of GENI for $1,763,527 on Dec 18 ’25. On Dec 15 ’25, another insider, Burns Daniel Paul, who serves as the Director of the company, bought 9,414 shares for $10.70 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GENI now has a Market Capitalization of 2687965952 and an Enterprise Value of 2510350080. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.72 while its Price-to-Book (P/B) ratio in mrq is 3.78. Its current Enterprise Value per Revenue stands at 4.153 whereas that against EBITDA is -26.97.
Stock Price History:
The Beta on a monthly basis for GENI is 1.85, which has changed by 0.22500002 over the last 52 weeks, in comparison to a change of 0.16067612 over the same period for the S&P500. Over the past 52 weeks, GENI has reached a high of $13.73, while it has fallen to a 52-week low of $8.15. The 50-Day Moving Average of the stock is 6.13%, while the 200-Day Moving Average is calculated to be 2.86%.
Shares Statistics:
According to the various share statistics, GENI traded on average about 5.29M shares per day over the past 3-months and 3089520 shares per day over the past 10 days. A total of 242.82M shares are outstanding, with a floating share count of 219.42M. Insiders hold about 8.08% of the company’s shares, while institutions hold 92.79% stake in the company. Shares short for GENI as of 1765756800 were 24118044 with a Short Ratio of 4.56, compared to 1763078400 on 19293458. Therefore, it implies a Short% of Shares Outstanding of 24118044 and a Short% of Float of 11.05.
Earnings Estimates
Current recommendations for the stock of the company come from 1.0 analysts. The consensus estimate for the next quarter is -$0.03, with high estimates of $0.02 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.3 and $0.3 for the fiscal current year, implying an average EPS of $0.3. EPS for the following year is $0.41, with 1.0 analysts recommending between $0.41 and $0.41.
Revenue Estimates
According to 17 analysts,. The current quarter’s revenue is expected to be $227.04M. It ranges from a high estimate of $234M to a low estimate of $225.8M. As of. The current estimate, Genius Sports Limited’s year-ago sales were $175.53MFor the next quarter, 17 analysts are estimating revenue of $174.72M. There is a high estimate of $181M for the next quarter, whereas the lowest estimate is $167.12M.
A total of 17 analysts have provided revenue estimates for GENI’s current fiscal year. The highest revenue estimate was $663.1M, while the lowest revenue estimate was $654.8M, resulting in an average revenue estimate of $656.03M. In the same quarter a year ago, actual revenue was $510.89MBased on 18 analysts’ estimates, the company’s revenue will be $785.25M in the next fiscal year. The high estimate is $835.9M and the low estimate is $729M.
